QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

[1]  Douglas L. Mann,et al.  Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th edition , 2018 .

[2]  R. Guimbaud,et al.  Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Santoro,et al.  A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Ahn,et al.  A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. , 2013, Lung cancer.

[5]  C. Porta,et al.  Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review , 2013, International journal of oncology.

[6]  P. Fasching,et al.  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Machiels,et al.  A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel , 2013, Journal of cardiovascular pharmacology.

[8]  R. Shah,et al.  Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) , 2013, Drug Safety.

[9]  E. Stanek,et al.  Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. , 2013, Mayo Clinic proceedings.

[10]  A. Tan,et al.  A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[11]  Thomas Krause,et al.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.

[12]  M. Neary,et al.  Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics , 2012, Medical Oncology.

[13]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[14]  Chiun Hsu,et al.  Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. , 2012, Journal of hepatology.

[15]  D. Nassal,et al.  Molecular Determinants of Pentamidine-Induced hERG Trafficking Inhibition , 2012, Molecular Pharmacology.

[16]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Culine,et al.  7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial , 2011 .

[18]  Chih-Hsin Yang,et al.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Van Cutsem,et al.  Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.

[20]  Douglas P. Zipes,et al.  Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 10th Edition , 2011 .

[21]  Y. Pithavala,et al.  Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers , 2010, Investigational New Drugs.

[22]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[23]  A. Tolcher,et al.  A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer , 2010, Cancer Chemotherapy and Pharmacology.

[24]  P. Catalano,et al.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma , 2010, Journal of surgical oncology.

[25]  M. Neary,et al.  Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review , 2010, BJU international.

[26]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[27]  H. Katus,et al.  Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Xin Huang,et al.  Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib , 2009, Clinical Cancer Research.

[30]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[32]  L. S. Fridericia.  Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken , 2009 .

[33]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Herbst,et al.  Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Seymour,et al.  Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Siu,et al.  Molecularly targeted oncology therapeutics and prolongation of the QT interval. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[38]  E. Perucca,et al.  Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. , 2003, British journal of clinical pharmacology.

[39]  L. S. Fridericia,et al.  The Duration of Systole in an Electrocardiogram in Normal Humans and in Patients with Heart Disease * , 2003, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[40]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[41]  Robert M Califf,et al.  What clinicians should know about the QT interval. , 2003, JAMA.

[42]  A J Camm,et al.  The QT Interval , 2010 .

[43]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[44]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .

[45]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[46]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[47]  D. Levy,et al.  An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) , 1992, The American journal of cardiology.

[48]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[49]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[50]  T. Choueiri,et al.  Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  A. Tsao.  Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) , 2012 .

[52]  P. Libby,et al.  Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 9th Edition Expert Consult Premium Edition €“ Enhanced Online Features , 2011 .

[53]  Robert O. Bonow,et al.  Heart Disease: A Textbook of Cardiovascular Medicine. 7th Edition , 2004 .

[54]  M. Hodges.  Bazett's QT correction reviewed : Evidence that a linear QT correction for heart rate is better , 1983 .